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A B S T R A C T
Statistics on cancer incidence from Central and South American countries are scarce because of the small
number of population-based cancer registries that continuously collect data. Similarly, comparable
statistics on cancer mortality are sparse in spite of efforts made to improve coverage in the last decade.
The aim of this study is to describe geographical patterns and trends in cancer incidence and mortality in
Central and South America in the 21st century. The primary objective was to obtain the best quality
cancer data available from each country within the region. Cancer incidence data were obtained from
population-based cancer registries within the region and, in countries where these did not exist, from
hospital-based registries; national mortality data were obtained from the World Health Organization
mortality database.
Given the variability in data quality – mainly due to the age and development in maturity of the
registries, an exhaustive review of the data was necessary in order to appropriately analyze, describe and
interpret patterns of cancer incidence and mortality between countries and within cancer-speciﬁc sites.
This paper presents the methods employed in the collection, quality control and analysis of the datasets
received for the project.
ã 2015 International Agency for Research on Cancer; Licensee Elsevier Ltd. This is an open access article
under the CC BY-NC-ND IGO 3.0 license (https://creativecommons.org/licenses/by-nc-nd/3.0/igo/).
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GLOBOCAN estimates have indicated that 1 million new cancer
cases and 500,000 cancer deaths occurred in the Central and South
American region in 2012. Projections indicate that by the year
2030, 1.7 million new cases and 1 million cancer deaths are
expected to occur in the region because of ageing and population
growth [1]. Although GLOBOCAN estimates are the most readily
available statistics on cancer in the region, they are based on the
data available in each country and may require complex methods
of estimation [2]. For example, to generate estimates of national
cancer incidence in Central and South America and the Caribbean,
for many countries GLOBOCAN 2012 uses national mortality and$ This is an Open Access article published under the CC BY-NC-ND 3.0 IGO license
which permits users to download and share the article for non-commercial
purposes, so long as the article is reproduced in the whole without changes, and
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reproduced in association with the promotion of commercial products, services or
any entity. There should be no suggestion that IARC endorses any speciﬁc
organisation, products or services. The use of the IARC logo is not permitted. This
notice should be preserved along with the article’s original URL.
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creativecommons.org/licenses/by-nc-nd/3.0/igo/).5-year relative cancer survival data. This methodology works
relatively well for cancers with a poor prognosis (lung or
pancreatic cancer) but it is less reliable for cancers with good
prognosis (melanoma, breast or prostate cancers) [2]. Statistics on
cancer incidence from Central and South American countries,
based on observed data, are scarce due to the low number of
population-based cancer registries continuously collecting rele-
vant information. High quality cancer registrations in the region,
included in the last edition of Cancer Incidence in Five Continents
(CI5) for the period 2003–2007, cover about 8% of the population
while in North America such registration coverage is 83% [3].
Although comparable statistics on cancer mortality are also sparse,
several summaries of cancer mortality have been published in
recent decades [4–12]. The aim of this project was to describe the
current patterns of cancer incidence and mortality in the Central
and South American region (including Cuba) in the 21st century by
obtaining the best available cancer data from each country within
the region. This paper presents the methods employed in the
collection, quality control and analysis of the datasets received for
the project.. This is an open access article under the CC BY-NC-ND IGO 3.0 license (https://
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The primary objective was to obtain the best-quality cancer
data available from each country within the region. Population-
based cancer registries located in the region that were on the
contacts database – maintained by the International Agency for
Research on Cancer (IARC) or that were member organizations of
the International Association of Cancer Registries, IACR (http://
www.iacr.com.fr/) or the Red de Institutos Nacionales de Cancer,
RINC (www.rinc-unasur.org/) between December 2012 and April
2013 – were invited to participate by submitting incidence data or
by providing consent to use cancer incidence data previously
submitted for any volume of Cancer Incidence in Five Continents
(CI5) [3]. To include as many countries as possible, those that did
not have a population-based cancer registry (PBCR) were invited to
participate by submitting data from pathology-based registries
and/or hospital-based cancer registries (HBCRs) as the best
available source of information. In order to provide a detailed
description of the cancer proﬁle in the Central and South American
region, nationwide cancer mortality data are also presented; these
are particularly relevant for countries where incidence data were
not available. The World Health Organization (WHO) collects the
total annual number of cancer deaths by country compiled by the
IARC as part of the WHO mortality database [13].
2.1. Geographical boundaries
According to the United Nations (UN) [14] the countries located
in Central America are: Belize, Costa Rica, El Salvador, Guatemala,
Honduras, Mexico, Nicaragua, and Panama; and the countries and
territories in South America are: Argentina, Bolivia (Plurinational
State of), Brazil, Chile, Colombia, Ecuador, French Guyana, Guyana,
Paraguay, Peru, Suriname, Uruguay, and Venezuela (Bolivarian
Republic of). The UN also lists the Falkland Islands (Malvinas)
within South America; however, they were not included in this
report because they are not part of the IACR or RINC.
Although Cuba is located within the Caribbean, it was included
with other countries from Central and South America in this study
because of the shared Latin-American heritage and culture. Cuba
also has cancer registries that are member organizations of the
International Association of Cancer Registries (IACR) and it is also
the only Caribbean member of the RINC organization. For
simplicity, data for Cuba are presented with those of Central
America. Therefore the Central and South American region, as
deﬁned throughout this supplement issue, refers to the 21 coun-
tries and territories listed above together with Cuba. In all papers
included in this supplement issue, the authors analyzed the
datasets using the same methods to estimate cancer incidence and
mortality rates.
2.2. Editorial board
The support and collaboration of the key leaders in the Central
and South American region, experts in public health with extensive
experience in cancer registries, were very important to ensure the
success and completion of this project. The Editoral Board was
composed of the following regional representatives: Dr Graciela
Abriata (Argentina), Dr Marise Rebelo (Brazil), Dr Marion Pineros
(Colombia), Dr Luis Eduardo Bravo (Colombia), Dr Leticia
Fernandez (Cuba), Dr Patricia Cueva (Ecuador), and Dr Enrique
Barrios (Uruguay), as well as the project leads: Dr Mónica Sierra
and Dr David Forman from the IARC. Editorial Board Members were
responsible for encouraging registry directors to participate in the
project, reviewing and/or co-authoring articles as a result of this
work, and providing support to disseminate the results of the
project.2.3. Data
2.3.1. Incidence data
An invitation letter (including the call for data), a questionnaire,
and an instruction manual were sent to all cancer registry directors
and coordinators in the country’s ofﬁcial language (Spanish,
Portuguese, English or French); registries had about 6 months to
respond to the data call. Registries that did not respond to the
original call received two reminders and then a written e-mail
from one of the Editorial Board Members. Several attempts were
made to contact key personnel in countries that had not submitted
data, including telephone calls to directors and/or e-mail and
postal invitation letters to the Ministry of Health.
All the participant registries were required to complete a
questionnaire that included background and history (year registry
started), geographic location, population size, year population-
based data ﬁrst became available, reporting facilities and data
sources, procedures for case ﬁnding and data abstraction, coding
methods, type of data collected on incident cases, and the methods
of follow-up for vital status. Consistent with the process for CI5 [3],
some of these variables provide insights into not only the size of
the registry or its coverage but also information regarding the
accuracy of registration (results from more recently established
registries should be interpreted with greater caution).
2.3.2. National mortality data
The mortality data used for this project were obtained from the
WHO mortality database [13]. Mortality data were derived from
vital registration systems where the underlying causes of death are
certiﬁed. The WHO yearly collects the total number of cancer
deaths by country. National population data were obtained from
the United Nations (UN), world population prospects, the
2012 revision (http://esa.un.org/wpp/).
2.4. Processing and checking: incidence data
The data submission and processing for this project followed
principles similar to those used by CI5 (see [3] for more details).
Registries were asked to submit the material (data, questionnaires,
consents) via the Registries Portal (https://cinportal.iarc.fr/),
although some registries submitted required information by e-
mail. All new data at the individual level collected for this project
were stored on a secure protected server at the IARC in the
Section of Cancer Surveillance (CSU), to which only a limited
number of identiﬁed staff members had access. These data (as per
their consent) will not be used for any other purpose or
transferred to any third party without the registries’ explicit
permission. The process of checking and validating the data was
iterative and required frequent communication and interactions
with the cancer registries; this took several months to complete
(Fig. 1). The following process applies to new data submissions;
while only selected sections apply for cancer registries that
provided written consent to use, previously submitted CI5 data had
already been checked and validated (see Fig. 1).
2.4.1. Incidence data (the number of newly diagnosed cases each year)
Registries were asked to submit the following data items for
each case: (1) unique identiﬁcation number (registration number);
(2) sex; (3) ethnic group or race (optional), (4) age and/or birth
date; (5) date of incidence; (6) site (topography) of the tumor; (7)
morphology of the tumor; (8) behavior of the tumor; (9) basis of
diagnosis; (10) tumor sequence number; and (11) registration date.
Other optional variables were vital status at last contact, date of
death, and date of last contact. Data were accepted in any format
(text or Excel ﬁles, or CanReg, MS Access, SPSS databases, etc.).
Most registries applied the standard deﬁnitions of incidence (i.e.
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recommended by the IARC/IACR [15], and only the registries of
Mendoza (Argentina), Belem (Brazil) and French Guyana used
the European Network of Cancer Registries recommendations [16].
Data items 6–8 were converted into ICD-O-3 using the
IARCcrgTools [17] program. The process was complex when
registries submitted alternative coding systems such as ICD-O-1,
ICD-O-2, or combinations of ICD-9 or ICD-10 topography with
ICD-O morphology (Fig. 1). Code veriﬁcations were made for:
sex, incidence date and, if provided, birth date, and ICD-O-
3 topography and morphology. Consistency checks were
performed between the following items: age versus birth/
incidence dates, sex versus site, sex versus histology, age versus
site, age versus histology, site versus histology, and basis of
diagnosis versus histology. Any conversion errors or unlikely or
rare combinations identiﬁed during this process were commu-
nicated to the registry (Fig. 1). After receiving a corrected or a
new ﬁle from the registries, the entire process was repeated to
ensure that no more errors were found. Using IARCcrgTools, the
database was checked for multiple primaries (multiple tumors)
following the IARC/IACR rules, or for duplicate registrations.Fig. 1. Flowchart of cancer registry data conversion, processing and analysis toOnce there were no more errors in the database, the ICD-O-
3 codes for topography and morphology were converted to ICD-
10 codes (Fig. 1).
2.4.2. Population data
Population-based cancer registries were asked to submit
population denominators based on a census for each individual
year of the reference period, by sex and 5-year age groups. Most
registries submitted populations at the mid-year of the period of
interest, while others provided data from two or more censuses for
which the data were extrapolated to obtain a more precise
estimate of the person-years at risk. Years of risk duration were
counted in person-years.
2.4.3. Case series
A process similar to that described in Section 2.4.1 was used to
process and check data from hospital-based cancer registries;
however, not all variables were submitted (i.e. date of incidence,
population denominators). Speciﬁcally, data checks for hospital-
based cancer registries included the following combinations: sex/
histology, histology/site, behavior/topography, behavior/histology, generate the Burden of Cancer in Central and South America Publication.
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multiple primaries; and conversion errors from any version of
ICD-O to ICD-10.
2.4.4. Inclusion criteria
All population-based cancer registries that submitted new
data or provided written consent to use data previously
submitted to the IARC were eligible to be included in the study.
Even though there has been no selection based on quality, all
datasets received were passed through the same standard data
quality control and checking procedures as used in CI5 [18], and
registries were then contacted to correct identiﬁed errors and
inconsistencies (Fig. 1). Pathology-based cancer registries that
submitted data were eligible to be included in the study after
passing through the same standard data quality control and
checking procedures as used in CI5 [18] (Fig. 1). Pathology-based
registries were asked for further information regarding sources of
information, coverage and exhaustiveness in order to assess
whether the estimation of incidence rates was appropriate. These
registries were also asked to submit population denominators
(see Section 2.4.2). Pathology-based registries were included if
the estimation of incidence rates of the population coverage was
80%. Likewise, all hospital-based cancer registries that submit-
ted data were eligible to be included in the study after passing
through similar standard data quality control and checking
procedures. HBCR submissions were not included from countries
with an existing PBCR.
2.5. Processing and checking: national mortality data
Mortality data quality based on completeness, coverage of the
registration, and the proportion of deaths assigned to ill-deﬁned
causes (ICD-10 codes: R00–R99, Y10–Y34, Y87.2, C76, C80, C97, I47.2,
I49.0, I46, I50, I51.4, I51.5, I51.6, I51.9, and I70.9) has been classiﬁed in
three levels: high, medium and low [19]. Based on this classiﬁcation,
mortality data for Cuba, Mexico and Venezuela were of high quality;
thoseforChile,Colombia,CostaRica,ElSalvador,Guatemala,Guyana,
Panama, and Uruguay were of medium quality; and those for
Argentina, Ecuador, Nicaragua,Paraguay, Peru,and Surinamewere of
low quality. The mortality data for Bolivia and Honduras has not been
available since 1990; therefore the quality of these data was not
evaluated [19].
2.5.1. Population data
To estimate countrywide mortality rates, national population
denominators (including all individuals susceptible to a speciﬁc
cancer) were obtained from the UN, world population prospects,
and the 2012 revision (http://esa.un.org/wpp/) for each individual
year of the reference period by sex and 5-year age groups. Years of
risk duration are counted in person-years.
2.5.2. Reallocation of deaths certiﬁed as “uterus, unspeciﬁed” and
combined deaths classiﬁed as “unspeciﬁed and corpus uteri”
Deaths coded as “uterus, unspeciﬁed” (ICD-10, C55) were
reallocated to either cervix uteri (C53) or corpus uteri (C54)
according to their respective age-speciﬁc and time-speciﬁc
distributions using the distributions of cervix uteri and corpus
uteri in a reference population with reliable death certiﬁcates, as
proposed by Loos et al. [20]. Deaths coded as “unspeciﬁed and
corpus uteri” (C54–C55) were ﬁrst divided into two components
using cancer mortality data proportions from a reference
population; and then “uterus, unspeciﬁed” (C55) deaths were
redistributed in cervix uteri (C53) and corpus uteri (C54) using
age-speciﬁc proportions from the same source [20] (Annex 1).2.6. Statistical analysis
Methods for computing rates and relevant measures have been
previously described for CI5; thus they will be mentioned here only
brieﬂy (for more details see [14,21,22]).
2.6.1. Incidence and mortality rates
Numbers of new cancer cases and deaths were grouped into
5-year time periods and 16 5-year age groups (0–4, 5–14, 15–19,
. . . 70–74, and 75+ years). Age-speciﬁc rates were estimated
using mid-period population denominators by age group and
sex. Crude incidence and mortality rates per 100,000 for each
cancer were estimated, as well as their percentage contribution
to a total number of cancers. Age-standardized rates per
100,000 were calculated using the direct method and the World
standard population [23,24], to facilitate comparisons between
populations with different age compositions as well with the
results from other international publications such as CI5.
National incidence rates (age-speciﬁc and age-standardized)
were estimated by aggregating the data from the available cancer
registries using a weighted average of local rates. The cumulative
rates of developing or dying from cancer before the age of
75 years (in the absence of competing causes of death) were also
calculated and expressed as a percentage. Age-standardized rates
and cumulative rates were corrected for cases of unknown age.
To correct for unknown age, the rate calculated on the basis of
cases of known age is multiplied by a correction factor. The
correction factor is the ratio between the total number of cases of
cancer of the same type in persons of the same sex and the
number of cases occurring in persons of known age. Such
correction is important to account for all registered cases and to
avoid underestimating the rates.
2.6.2. Proportion of microscopic veriﬁcation (incidence data)
The proportion of cases microscopically veriﬁed (MV) is
estimated as the proportion of microscopic veriﬁcation of a
tissue specimen for each site by sex, as well as by histology or
cytology/hematology. The MV percentage is a measure of validity
of the diagnostic information [21,22]. A very high MV% – higher
than might reasonably be expected – suggests over-reliance on
pathology laboratories as the source of diagnosis, suggesting
deﬁciencies in case-ﬁnding from other sources [3]. Annex
2 includes tables showing the percentage of MVs by sex, country
and registry location for the following sites: oral cavity and
pharynx (ICD-10, C00–14), esophagus (C15), stomach (C16),
colon, rectum and anus (C18–21), liver (C22), pancreas (C25),
larynx (C32), trachea, bronchus and lung (C33–34), melanoma of
skin (C43), breast (C50), cervix uteri (C53), corpus uteri (C54),
ovary (C56), prostate (C61), testis (C62), kidney (C64), bladder
(C67), brain and central nervous system (C70–72), thyroid (C73),
Hodgkin lymphoma (C81), non-Hodgkin lymphoma (C82–85,
C96), leukemia (C91–95), other and unspeciﬁed, all sites except
non-melanoma skin cancer (C00–96/C44), and all sites (C00–96).
2.6.3. Death certiﬁcate only (incidence data)
The proportion of cases identiﬁed by death certiﬁcate only
(DCO) is estimated for each site by sex. Death certiﬁcates are an
important supplementary source of information for cancer
registries; they are used when there is no information available
other than a death certiﬁcate mentioning cancer [21,22]. DCOs are
a measure of validity since death certiﬁcates often rely on second-
hand information which can be inaccurate or imprecise as
compared with that obtained from clinical or pathology records
[3].
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Yearly age-standardized incidence and mortality rates per
100,000 were calculated using the direct method and the world
standard population [23,24]. To illustrate the direction of the
trends in incidence and mortality rates by cancer site, locally
weighted regression (LOWESS) curves were ﬁtted to provide
smoothed lines through the scatterplot of the annual age-
standardized rates by calendar period, and analyzed by ﬁtting
linear regression model [25]. For this report, smooth lines were
computed using a bandwidth of 0.5, which means that 50% of the
annual time-series data was used to determine the LOWESS
plotting position for each year. Rates were plotted on a semilog
scale. To describe incidence and mortality time trends for the
most recent 10-year period, the estimated annual percentage
change (EAPC) was calculated using the method proposed by
Esteve et al. [26]. EAPC in age-standardized incidence and
mortality incidence rates by cancer site were estimated using a
log-linear regression model with a Poisson distribution, through
the maximum likelihood procedure, using the calendar year as
the regression variable, rejecting the null hypothesis that EAPC
equals to zero if the resulting P-value was <0.05. Changes in rates
comprised a shift in the magnitude or a change in the direction of
the rate; for example, a positive EAPC indicates an increasing trend
while a negative EAPC indicates a decreasing trend. Trends in
incidence and EAPCs were estimated only for those registries and
countries that provided written consent to use their data or that
submitted new data for approximately 10 years. Mortality data
were matched to the same time-period to generate time trends
and EAPCs.Table 1
Cancer registries in Central and South America registered within the IARC/IACR databa
Country Cancer registriesa(as of Dec–April/2013) 
Invited Participants 
CENTRAL AMERICA
Belize 1 0
Costa Rica 1 1 
Cuba 15 1 
El Salvador 1b 1b
Guatemala 2c 2c
Honduras 2c 1c
Mexico 1b 1b
Nicaragua 2c 1c
Panama 2c 1c
Subtotal 27b,c 9b,c
SOUTH AMERICA
Argentina 16 8d
Bolivia 1 1
Brazil 26 19 
Chile 3 2 
Colombia 4 4 
Ecuador 2 2 
French Guyana 1 1
Guyana 1 0
Paraguay 1c 1c
Peru 4 4e
Suriname 1c 0
Uruguay 1 1 
Venezuela 1c 1f
Subtotal 62c 44c
TOTAL 89c 53b,c
a A current list of all the cancer registries in the region can be found here.
b Includes histopathology-based cancer registries.
c Includes hospital-based cancer registries.
d One registry excluded because after data cleaning only seven cancer cases remaine
e One registry excluded because of lack of response to queries after data processing.
f One registry excluded because format of data could not be used. http://www.iacr.c2.6.5. Software
All the necessary programs to prepare the data for IARCcrgTools
[17] (for checks and conversions) and for analysis were written in
Stata version 12.1 (StataCorp) [27]. The tables produced were
generated in PostScript format for printing purposes, and after
validation, converted into PDF ﬁles using LaTeX [28] prior to
publication.
2.7. Presentation of the data
These systematic analyses resulted in a comprehensive overview
of the cancer burden in the 22 countries and territories in the Central
and South American region. In this supplement issue, papers 3–
17 include a set of tables containing the country estimates for
incidence and mortality, by sex, and a set of ﬁgures to illustrate the
estimated annual percentage change in age-standardized incidence
and mortality rates for 14 cancer-speciﬁc sites, by sex, with LOWESS
smoothing presented in semi-logarithmic scale.
The following results for each registry and for the country
summary are available online through the “Cancer in Central and
South America” website hosted by the Section of Cancer
Surveillance at IARC (http://www-dep.iarc.fr/CSU_resources.htm):
 A set of tables containing the annual number of cancer cases
(incidence and deaths), and the annual age-standardized
incidence and mortality rates for 11 major cancer diagnosis
groups, by sex. The following groups were included (ICD-
10 codes): lip, oral cavity, and pharynx (C00–C14), digestive
organs (C15–C26), respiratory organs (C30–C39), bone, cartilage,ses between December 2012 and April 2013.
Cancer Incidence in Five Continents Vol. X
Submitted Accepted
1 1
2 1
3 2
7 4
12 6
3 3
4 4
2 2
1 1
29 20
32 22
d.
om.fr/members/latinamerican.
Table 2
Background of participant cancer registries located in Central South America.
Country Registry location Registry type Included in
incidence
analysis
Area covered Estimated population,
mid-point for
most recent
5-year perioda
Non-residents
treated inside
registration area (%)
Cancer
reportable
Year registry
started
Year population-
based data ﬁrst
available
Data available
for period
CENTRAL AMERICA
Costa Rica PB Yes National 4,263,000 NA Yes 1977 1980 1980–2007
Cuba Villa Clara PB Yes Province 813,000 NA Yes 1995 1964 2004–2007
El Salvador PB Yes Subnationalb 5,744,113 NA No 1987 1987 1999–2003
Guatemala Guatemala PB No Regional ND NA NA 1995 1995 ND
Guatemala HB No Regional 2,541,581 NA NA 1995 1995 2003–2007
Honduras Cortes & Francisco Moran HB No Regional 2,660,346 DK No 1997 2002 2002–2005
Mexico Jalisco PB Yes Province 6,752,113 8 Yes 1993 1993 2005–2010
Nicaragua Leon HB No Regional NA NA NA 1987 NA 2009–2010
Panama HB No Subnationalb 3,475,741 NA Yes 2012 NA 2003–2009
SOUTH AMERICA
Argentina Bahía Blanca PB Yes City 291,000 15 No 1989 1989 1996–2007
Chaco PB Yes Province 1,055,259 10 Yes 1999 2002 2002–2010
Córdoba PB Yes Province 1,322,000 0 Yes 2003 2003 2004–2007
Mendoza PB Yes Province 1,637,000 5 Yes 2000 2003 2004–2007
Neuquen PB Yes Province 510,106 5 Yes 2003 2003 2003–2007
Santa Fe PB Yes Province 3,177,557 NA No 2002 2003 2003–2006
Tierra del Fuego PB Yes Province 115,000 NA Yes 2003 2003 2003–2007
Bolivia La Paz PB Yes City 1,893,640 5 Yes 2011 2012 2011
Brazil Aracaju PB Yes City 492,000 NA No 1996 1996 1996–2006
Belem PB Yes Regional 1,400,000 DK No 1989 1989 1989–1991
Belo Horizonte PB Yes City 2,336,000 NA No 2000 2000 2003–2005
Campinas PB Yes City 435,190 ND ND 1992 1991 1991–1995
Campo Grande PB Yes Regional 786,797 NA Yes 2000 2001 2000–2003
Cuiabá PB Yes City 768,000 60 No 1999 2000 2000–2006
Curitiba PB Yes City 1,757,903 DK No 1997 1998 2003–2007
Fortaleza PB Yes City 2,335,000 30 No 1971 1983 1990–2006
Goiânia PB Yes City 1,194,000 40 No 1986 1988 1993–2007
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Jau PB Yes City 123,374 No No 2000 2000 2000–2009
Joao Pessoa PB Yes City 660,797 75 No 2000 2001 2003–2006
Manaus PB Yes City 1,644,688 30 No 2001 2001 2000–2005
Natal PB Yes City 712,317 0 No 1996 1997 2000–2004
Pocos Caldas PB Yes City 157,324 1 No 2007 2007 2007–2011
Porto Alegre PB Yes City 1,428,694 DK No 1973 1973 2003–2005
Recife PB Yes City 1,501,010 No No 1996 1996 1998–2005
Salvador PB Yes City 2,673,557 DK No 1996 1996 1996–2005
SãoPaulo PB Yes City 10,896,000 30 No 1969 1969 1993–2007
Teresina (Piaui) PB Yes Regional 788,770 35 No 2000 2000 2000–2002
Chile Region of Antofagasta PB Yes Regional 541,000 2 Yes 1998 1998 2003–2007
Valdivia PB Yes Regional 372,000 0 Yes 1992 1993 1993–2008
Colombia Bucaramanga PB Yes Regional 1,024,000 50 No 2000 2000 2003–2007
Cali PB Yes City 2,041,000 40 No 1962 1962 2003–2007
Manizales PB Yes City 377,000 40 No 2001 2002 2003–2007
Pasto PB Yes City 382,000 61 Yes 1998 1998 2003–2007
Ecuador Cuenca PB Yes Canton 455,000 55 No 1996 1996 2003–2007
Quito PB Yes City 1,521,000 52 No 1984 1985 2003–2007
French Guyana PB Yes Regional 178,347 0 No 2005 2005 2003–2008
Paraguay HB No Subnationalb 6,653,184c 2 No 1998 2011 2011
Peru Arequipa PB Yes City 780,924 18 Yes 2000 2002 2002–2003
Lima PB Yes City 8,489,669 55 No 1990 1990 2004–2005
Trujillo PB Yes Regional 613,815 DK No 1990 1994 1998–2002
Uruguay PB Yes National 3,315,000 0 Yes 1987 1987 2005–2007
PB, population-based; HB, hospital-based; ND, no data; NA, question not answered; DK, don't know.
a Some registries provided data for a shorter time period.
b Incomplete national coverage.
c According to the most current census for the corresponding period.
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male genitalia (C60–C63), urinary organs (C64–C68), eye, brain,
and thyroid (C69–C75), hematopoietic (C81–C96), “other and
unspeciﬁed”, and “all sites” (C00–96).
 A set of tables containing age-speciﬁc incidence and mortality
rates for a 5-year period (when possible) for 35 types of cancer
(Annex 3) for 5-year age groups (0–4, 5–14, 15–19, . . . 70–74,
and 75+ years); and summary rates (crude, age-standardized),
percentage of MV cases (incidence data only), percentage of DCO
cases (incidence data only), and ranking across speciﬁc cancer
types based on the age-standardized rates (not including in the
ranking “all sites”, C00–96, or “all sites but C44”).
 The estimated population at risk, with the source of information
in the form of a population pyramid by sex and age, and the
method of estimation used (population pyramids).
 Age-speciﬁc incidence and mortality rates plots for 24 cancer
sites (ICD-10 codes: C15, C16, C18–21, C22, C23–24, C25, C32,
C33–34, C43, C50, C53, C54, C56, C60, C61, C62, C64, C67, C70–72,
C73, C81, C82–85,96, C91–95, C00–96 except C44) by sex,
presented on a semi-logarithmic scale.
 Trends in age-standardized incidence and mortality rates for 24
cancer sites (ICD-10 codes: C15, C16, C18–21, C22, C23–24, C25,
C32, C33–34. C43, C50, C53, C54, C56, C60, C61, C62, C64, C67,
C70–72, C73, C81, C82–85,96, C91–95, C00–96 except C44), by
sex, with LOWESS smoothing presented in semi-logarithmic
scale.
 A set of ﬁgures presenting country estimates for age-standard-
ized incidence and mortality rates, by sex.
3. Results
In total, 88 (77 population-based, two histopathology based,
and nine hospital-based) cancer registries were invited to
participate in this publication; 53 (60%) responded to the data
call, 22 of which were previously accepted for CI5 Volume X
(Table 1). All registries that submitted data were included in the
project except for one cancer registry in Argentina where only
seven cancer cases remained after the data processing protocol,
and one cancer registry in Peru because the registry failed to
respond to queries after data processing. One hospital-based
cancer registry was excluded from the current report because the
data received had no codes with which to conduct any quality
control data checks.Table 3
List of registries included in the national incidence rate estimation during the most re
Country Number of registries Regist
Argentina 7 Bahia 
Santa 
Bolivia 1 La Paz
Brazil 16 Aracaj
Curitib
Natal, 
Paulo
Chile 2 Antofa
Colombia 4 Bucara
Costa Rica 1 Nation
Cuba 1 Villa C
Ecuador 2 Cuenc
El Salvadora 1 El Salv
French Guyana 1 French
Mexicoa 1 Jalisco
Peru 3 Arequ
Uruguay 1 Nation
a Histopathology-based cancer registry.3.1. Cancer registry characteristics
Table 2 and Annex 4 present the background characteristics of
all the participant cancer registries. Most cancer registries – except
for the registries in Costa Rica and Uruguay – were regional.
Registration activities began in the mid-1990s in the majority of
Central and South American countries. The oldest population
cancer registries in the region were Cali in Colombia, Sao Paulo,
Fortaleza, and Porto Alegre in Brazil, and Costa Rica (national),
whereas the newest registry was La Paz in Bolivia. In most
countries, cancer is not a reportable disease.
3.2. Incidence
Incidence data were available from most countries except
Belize, Guatemala, Guyana, Honduras, Nicaragua, Panama,
Paraguay, Suriname, and Venezuela. Excluding the HBCRs, all
cancer registries were included in the estimation of incidence rates
(Table 2). However, registries with the most current data were
included in the national incidence estimation for the most recent
5-year period (Table 3).
3.3. Incidence data quality indicators
Table 4 shows the percentage of MVs and DCOs by sex, country
and registry location for all cancer sites except C44. For most
registries, the MV% ranged from 60% to 97%, except for the
registries of Chaco and Neuquen in Argentina and Campo Grande in
Brazil with 44–57% of the cases being MV, and Jalisco in Mexico
with 100% of the cases MV. The percentage of DCO cases ranged
from 0% to 45%. The highest DCO%s were recorded in Chaco,
Neuquen, and Bahia Blanca in Argentina and Natal, Manaus, Campo
Grande, Teresina, Porto Alegre, Santa Fe, Recife in Brazil. Negligible
DCO% were recorded in ﬁve Brazilian registries, two in Peru, one in
El Salvador, one in Bolivia, French Guyana, and Mexico (ranging
from 0% to 1.7%). Annex 2 shows MV% and DCO% for all cancer sites
evaluated in this project.
3.4. Mortality
Mortality data were available from all countries except for
Bolivia, French Guyana, Guyana, and Honduras. The mortality data
coverage varied, with nine countries having 90% coverage, four
with 80–90%, and ﬁve with <80% [19] (Table 5).cent period of evaluation.
ry location Period
Blanca, Chaco, Cordoba, Mendoza, Neuquen,
Fe, Tierra del Fuego
2003–2007
 2011
u, Belo Horizonte, Campo Grande, Cuiaba,
a, Fortaleza, Goiania, Jau, Joao Pessoa, Manaus,
Pocos Caldas, Porto Alegre, Recife, Salvador, Sao
2003–2007
gasta, Valdivia 2003–2007
manga, Cali, Manizales, Pasto 2003–2007
al 2003–2007
lara 2003–2007
a, Quito 2003–2007
ador 1999–2003
 Guyana 2003–2007
 2006–2010
ipa, Lima, Trujillo 2001–2005
al 2005–2007
Table 4
Data quality indicators for all cancer sites combined excluding non-melanoma skin cancer, by period and sex.
Country City Period Males Females
Cases MV (%) DCO (%) Cases MV (%) DCO (%)
Argentina Bahia Blanca 1993–1997 2687 73.2 18.8 2974 75.6 15.0
Bahia Blanca 2003–2007 2307 84.6 14.5 2490 85.2 14.1
Chaco 2002–2005 3191 54.9 44.8 3285 64.4 35.5
Chaco 2006–2010 4387 67.7 18.4 4797 76.4 13.3
Cordoba 2004–2007 6451 81.3 16.4 7638 82.7 15.2
Mendoza 2003–2007 9835 81.9 14.4 10861 85.5 11.7
Neuquen 2003–2007 2571 43.9 38.0 2904 42.1 28.2
Santa Fe 2003–2006 2732 71.2 19.2 3058 74.5 19.2
Tierra del Fuego 2003–2007 395 82.8 3.0 425 87.8 4.0
Bolivia La Paz 2011 432 94.0 0.0 918 94.1 0.0
Brazil Aracaju 1996–2000 1539 79.3 15.8 2490 89.6 8.1
Aracaju 2002–2006 2305 88.2 8.9 1898 84.1 11.6
Belem 1989–1991 1775 61.3 16.6 2505 78.4 12.4
Belo Horizonte 2003–2005 8257 86.4 12.4 7984 85.6 12.8
Campinas 1991–1995 2908 86.4 3.9 3103 88.0 3.4
Campo Grande 2000–2003 1752 56.7 26.3 2102 67.2 17.7
Cuiaba 2000–2002 1530 74.6 0.0 2283 84.4 10.4
Cuiaba 2003–2006 2422 83.8 12.3 1593 76.2 0.0
Curitiba 2003–2007 8309 79.9 18.2 9050 83.4 15.4
Fortaleza 1990–1994 4151 77.8 15.6 9749 85.5 12.1
Fortaleza 2002–2006 7611 83.4 14.2 6400 82.7 10.5
Goiania 1993–1997 3134 89.5 6.9 7433 93.1 4.7
Goiania 2003–2007 7975 91.7 5.7 3586 91.3 5.5
Jau 2000–2004 769 95.4 1.7 747 93.7 0.7
Jau 2005–2009 884 92.6 0.9 613 93.1 3.4
Joao Pessoa 2003–2006 1759 96.6 0.5 2477 96.7 0.5
Manaus 2001–2005 3254 60.2 26.4 4072 71.6 20.1
Natal 2000–2004 3038 61.2 26.4 3741 66.6 23.8
Pocos Caldas 2007–2011 1082 91.8 5.9 860 91.3 6.9
Porto Alegre 2003–2005 7493 74.9 20.6 7864 77.6 18.0
Recife 1998–2001 3792 65.9 0.0 4723 68.9 15.7
Recife 2003–2005 3143 61.9 19.2 5858 71.1 0.0
Salvador 1996–2000 8172 75.8 7.6 9792 78.6 7.1
Salvador 2001–2005 9388 74.4 14.5 10258 73.5 15.8
Sao Paulo 1997–2001 69243 79.3 1.6 74574 79.1 1.1
Sao Paulo 2005–2009 73865 87.7 2.4 86311 86.2 1.7
Teresina 2000–2002 915 66.7 24.8 1330 72.4 17.4
Chile Antofagasta 2003–2007 2556 71.9 17.8 2258 77.6 13.2
Valdivia 1993–1997 1417 71.1 9.9 1472 72.6 8.0
Valdivia 2004–2008 2360 82.9 5.3 2117 78.5 6.0
Colombia Bucaramanga 2003–2007 3777 83.3 8.9 4487 85.4 7.5
Cali 2003–2007 9616 83.5 4.9 11426 87.1 3.8
Manizales 2003–2007 1476 88.6 6.7 1834 90.8 4.4
Pasto 2003–2007 1121 79.6 11.0 1497 84.5 8.4
Costa Ricaa Costa Rica 1985–1989 7078 78.0 0.0 16131 83.4 7.5
Costa Rica 2003–2007 16494 77.3 10.4 7072 80.9 0.1
Cuba Villa Clara 1995–1997 2896 62.2 12.0 3895 78.3 6.9
Villa Clara 2004–2007 4622 73.5 8.7 2355 67.8 10.8
Ecuador Cuenca 2003–2007 1147 78.8 5.3 1601 80.7 4.6
Quito 2003–2007 5452 86.3 8.4 6756 87.1 8.0
El Salvadora,b El Salvador 1999–2003 2439 82.1 0.1 7328 91.1 0.1
French Guyana French Guyana 2003–2008 976 83.6 0.0 704 93.6 0.0
Mexico Jalisco 2006–2010 13401 100.0 0.0 17491 100.0 0.0
Peru Arequipa 2002–2003 724 77.9 0.0 1229 78.8 0.0
Lima 2004–2005 11929 74.9 17.0 14303 77.4 14.5
Trujillo 1998–2002 1256 94.7 1.3 1947 95.5 1.5
Uruguaya Uruguay 2005–2007 19655 74.8 15.0 17688 79.3 13.6
a National coverage.
b Covers 80% of the population.
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Table 5
Summary of national mortality data available to the World Health Organization from Central and South America with data quality indicators [13].
Country Period Populationa,g Cancer deaths Mortality data quality indicators (all causes)
Number Unk. Age Civil registration coverage of cause of death (%)b Ill-deﬁned causes in
cause-of-death registration (%) 2007–2009c
CENTRAL AMERICA
Belize 2003–2007 1,404,721 793 0 90–100 10
Costa Rica 1985–1989 14,207,789 11,112 22 90–100 ND
Costa Rica 2003–2007 21,539,884 17,218 7 90–100 5d
Cuba 2004–2007 45,023,023 78,222 3 90–100 T6e
El Salvador 1999–2003 21,138,514 15,204 0 70–79 24
Guatemala 2003–2007 63,614,240 32,092 0 80–89 17
Honduras ND ND ND ND N/A N/A
Mexico 2006–2010 568,135,142 331,025 225 90–100 5e
Nicaragua 2003–2007 27,125,800 9786 0 60–69 5d
Panama 2003–2007 16,191,111 11,381 0 80–89 9
SOUTH AMERICA
Argentina 2003–2007 193,415,119 280,333 478 90–100 22
Bolivia ND ND ND ND N/A N/A
Brazil 2003–2007 929,249,696 730,374 0 80–89 12e
Chile 2003–2007 81,495,659 101,735 0 90–100 6
Colombia 2003–2007 215,207,051 154,115 471 90–100 6
Ecuador 2003–2007 67,075,079 38,692 0 70–79 16e
French Guyana ND ND ND ND N/A N/A
Guyana ND ND ND ND N/A N/A
Paraguay 2003–2007 29,488,298 14,535 0 70–79 18e
Peru 2001–2005 134,524,670 71,509 0 60–69 6.5f
Suriname 2003–2007 2,494,379 1551 0 80–89 13
Uruguay 2005–2007 9,980,019 22,232 0 90–100 17
Venezuela 2003–2007 133,322,657 91,035 0 90–100 8
ND, No data; N/A, not applicable; Unk., unknown.
a Source: UN, World population prospects, the 2012 revision http://esa.un.org/wpp/.
b Estimated level of coverage of deaths that are registered with cause-of-death information.
c The percentage of total deaths that has been assigned to ill-deﬁned causes as reported to the WHO.
d Period 2009–2011.
e Period 2008–2010.
f Period 2007.
g Population corresponds to the sum of the period.
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Argentina, Brazil, Chile, and Costa Rica were the only countries
included in the analysis of incidence and mortality time trends.
Incidence data covered 100% of the Costa Rican population but only
1–2% of the Argentinean, Brazilian and Chilean populations
(Table 6).
4. Discussion
The goal of this project was to collect incidence data from one or
more cancer registries from every country located in Central and
South America. Collecting and analyzing data in such a large area
(22 countries and territories) in a systematic and comparable way
was a major undertaking given the variability in data quality (due
mainly to the age and development in maturity of the registries).
Hence, an exhaustive review of the data was necessary in order to
appropriately analyze, describe and interpret patterns of cancer
incidence and mortality between countries and within cancer-
speciﬁc sites. We also compiled national mortality data fromTable 6
Countries and registries included in the analysis of time trends.
Countrya Name of registries included 
Argentina Bahia Blanca 
Brazil Aracaju, Fortaleza, Goiania, Sao Paulo 
Chile Valdivia 
Costa Rica National registry 
a National mortality data were matched to similar time periods as incidencesimilar time periods as incidence data for all Central and South
American countries to provide a more detailed description of the
cancer burden in the region.
To ensure data comparability, all cancer registries included in
this project underwent the same careful revision and validation as
used for CI5, but the inclusion criteria were less stringent. Although
some registries may supply suboptimal data quality, they
represents the best available data for each country. National
incidence data are lacking for most Central and South American
countries (except for Costa Rica and Uruguay), therefore nation-
wide incidence rates are represented by aggregated data from
regional registries which do not cover the entire country. Cancer
registration between and within countries may differ in com-
pleteness and data quality which, among other factors, depend on
the maturity of the cancer registry (i.e. Bolivia). Incidence rates
could be inﬂuenced by differences in case ascertainment and
reporting of certain cancers across countries and registries within
the region. Using data quality indicators, most cancer registries
were within the regional MV% mean values for all cancers
combined (excluding non-melanoma skin cancer) with a fewPeriod National coverage (%)
1993–2007 0.8
1997–2006 8.0
1993–2008 2.2
1985–2007 100.0
 data.
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establish an objective criterion for an acceptable DCO%, as it
depends on the local circumstance [29], there was a large
percentage of cases identiﬁed by DCO in nine registries (ranging
from 19% to 45% of the cases) which raises questions about the
validity of the data [29].
The histopathology-based cancer registries of El Salvador and
Jalisco State (Mexico) were included in the estimation of incidence
due to the large coverage of the population and exhaustiveness of
data collection which may provide useful estimates of the true
incidence for several cancer sites. The registry of El Salvador
includes passive data collection from 30 hospitals (pathology
reports) within the country and active data collection from the
hospital-based registry Instituto del Cáncer de El Salvador (I.C.E.S)
and Rosales National Hospital and the mortality registry of San
Salvador department (19 municipalities). It was reported that 80%
of the population was covered by the registry at mid-2005 based
on attention to patients that cover the public hospitals network
(based on questionnaire). The registry of Jalisco State (Mexico) is
coordinated by the Secretary of Health of Jalisco and is part of the
registry of histopathological neoplasias of Mexico; it collaborates
with all public and private institutions that make up the health
sector. The registry covers all cancer cases diagnosed in the state of
Jalisco from both public and private institutions (based on
questionnaire). The network of reporting consists of public, private
and social institutions as the Secretary of Health of Jalisco, the
Mexican Social Security Institute, Institute for Social Security and
Services for State Workers, Regional Military Hospital, Civil
Hospital, Hospital General Zapopan, PEMEX and the University
of Guadalajara, as well as private hospitals, Cancer Society, and
pathologists, oncologists and hematologists [30]. The percentage
of cancer cases missed by the registry is thought to be low,
although it has not yet been formally evaluated.
The quality of national mortality data rely on completeness,
coverage of the registration, and the proportion of deaths classiﬁed
as due to “ill-deﬁned” causes. Cancer mortality data quality in
some countries of the Central and South American region may be
considered to have medium or low quality (<90% coverage) [19].
However, mortality data provide valuable information to describe
the cancer burden since it may be the only source of information
available on cancer. Even though data from the WHO mortality
database was available for several countries in the region, only
countries that had both incidence and mortality data available
were included in the analysis of time-trends in order to distinguish
possible determinants of observable change over time: e.g. early
detection, risk factor or poor treatment.
In this study we included the best-quality cancer data available
from each country located in the region, covering 10% of the
population, greater than what was reported in CI5. In the cancer-
speciﬁc papers presented in this volume, we describe incidence
and mortality patterns of the following 14 cancer types: (ICD-10):
head and neck (C01–C14, C32), esophagus (C15), stomach (C16),
colorectal (C18, C19–20), gallbladder (C23–24), lung (C33–34),
melanoma of skin (C43), breast (C50), cervix (C53), prostate (C61),
brain and central nervous system (C70–72), thyroid (C73), Hodgkin
lymphoma (C81), and non-Hodgkin lymphoma (C82–85, C96). We
also included an overall summary paper for all cancer sites.
5. Conclusion
While enormous efforts have been made to increase the
number of cancer registries in Central and South America, there is
still an important challenge to increase population coverage in
order to present better estimations of the cancer burden. Data
patterns presented in this study must be interpreted with cautionbecause countrywide incidence rates are represented by aggregat-
ed data from regional cancer registries which do not cover the
entire country, with the exception of the national cancer registries
of Costa Rica and Uruguay. This study highlights the importance of
the data generated by population-based cancer registries as a
crucial element for cancer control planning.
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